Apnimed 提交首次公開募股申請，其每日僅需服用一次的 OSA 藥丸即將獲得美國食品藥物管理局（FDA）的審核決定
Apnimed, the company behind what could become the first oral pharmacotherapy for obstructive sleep apnea (OSA), has filed for an initial public offering in the United States. The company is expected to list on Nasdaq under the ticker APMD. The filing comes at a notable moment for the biotech sector. [...]
